The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pulsed dosing of erlotinib for central nervous system (CNS) progression in EGFR-mutant non-small cell lung cancer (NSCLC).
David Michael Jackman
Consultant or Advisory Role - Foundation Medicine; Genentech; Infinity
Honoraria - Chugai Pharma
Stacy L. Mach
No relevant relationships to disclose
Jennifer C. Heng
No relevant relationships to disclose
Michael S. Rabin
No relevant relationships to disclose
David Allen Barbie
No relevant relationships to disclose
Leena Gandhi
No relevant relationships to disclose
J Paul Marcoux
No relevant relationships to disclose
Daniel Botelho Costa
Consultant or Advisory Role - AstraZeneca; Pfizer; Roche